Abstract:By comparing standard antagonist regimen and agonist-antagonist protocol (AAP regimen), a combination of a microdose flare-up GnRH agonist with a GnRH antagonist in POSEIDON group 3 and group 4 patients with diminished ovarian reserve, this article aims to study if AAP regimen could improve the clinical outcomes in low prognosis patients. This is a retrospective study. The clinical data of 646 cycles of prospective poor ovarian response POR patients (POSEIDON group 3 and 4) who received in vitro fertilization and embryo transfer (IVF-ET) in Peking University Third Hospital reproductive medical center from January 2016 to May 2018 were retrospectively analyzed. The total number of APP cycle was 323, and the control group was selected from the database with 1:1 matching of prospective low prognosis patients (POSEIDON group 3 and group 4) with similar age and approaching date of oocyte retrieval. Patients' general information, ovarian hyperstimulation indicators and clinical outcomes were studied. AAP group had fewer antral follicle count (3.04±2.05 vs. 3.84±2.17, p<0.05) and similar AMH level (0.62±0.64 and 0.63±0.49, p>0.05) compared with control group. AAP group had shorter (9.84±2.59 vs. 10.31±2.23, p=0.015) and lower dosage (2754.18±973.37 vs. 3246.7±1044.20, p<0.05) of Gn using, and had similar number of oocytes obtained compared with control group (4.06±2.89 vs. 4.16±2.65, p=0.649). Under the same proportion of fertilization schemes (routine or ICSI methods), AAP group had higher fertilization rate (74.1% vs. 69.1%, p=0.004) and good quality embryo rate (62.6% vs. 56.9%, p=0.014), and ultimately had higher embryo implantation rate (22.3% vs. 15.8%, p=0.020) and cumulative clinical pregnancy rate (32.5% vs. 22.9%, p=0.018). For POSEIDON patients with low prognosis and poor ovarian reserve, controlled ovarian hyperstimulation with agonist-antagonist protocol had better clinical outcomes compared with conventional antagonist regimen.

APPLICATION OF CONTROLLED OVARIAN HYPERSTIMULATION WITH AGONIST-ANTAGONIST PROTOCOL IN POSEIDON GROUP 3 AND GROUP 4 PATIENTS WITH DIMINISHED OVARIAN RESERVE.